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(40.4 ± 15.7 years, 44.3% males) was 18.0 ± 4.7 ￿mol/l. While no ZD (<11 ￿mol/l) was observed, we
found low zinc levels (<15.1 ￿mol/l) in 28 patients (28.9%). Males had higher zinc levels compared with
females (19.4 ± 5.7 16.8 ± 3.3, = 0.006). Patients with low zinc levels more often reported depression
symptoms compared with patients with higher levels (27.3 9.4%, = 0.047). In a multivariate analysis,
zinc levels were an independent negative predictor for depression symptoms [odds ratio (OR) 0.727, 95%
confidence interval (CI) 0.532-0.993, = 0.045]. Zinc levels of patients with a complicated disease course
were not different from those of patients without (17.7 ± 4.3 18.3 ± 5.1, n.s.). Baseline zinc levels did
not predict disease outcome regardless of ATG16L1 genotype. Conclusion Low-normal zinc levels were
an independent predictor for the presence of depression symptoms in CD patients. Zinc levels at baseline
did not predict a complicated disease course, neither in CD patients overall, nor ATG16L1 carriers.
DOI: https://doi.org/10.1177/1756283X18757715
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-158464
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Greuter, Thomas; Franc, Yannick; Kaelin, Matthias; Schoepfer, Alain M; Schreiner, Philipp; Zeitz,
Jonas; Scharl, Michael; Misselwitz, Benjamin; Straumann, Alex; Vavricka, Stephan R; Rogler, Gerhard;
von Känel, Roland; Biedermann, Luc (2018). Low serum zinc levels predict presence of depression
symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn’s disease patients.
Therapeutic Advances in Gastroenterology, 11:1756283X18757715.
DOI: https://doi.org/10.1177/1756283X18757715
2
https://doi.org/10.1177/1756283X18757715 
https://doi.org/10.1177/1756283X18757715
Ther Adv Gastroenterol
2018, Vol. 11: 1–15
DOI: 10.1177/ 
1756283X18757715
© The Author(s), 2018. 
Reprints and permissions:  
http://www.sagepub.co.uk/
journalsPermissions.nav
Therapeutic Advances in Gastroenterology
journals.sagepub.com/home/tag 1
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Noninvasive monitoring of disease
activity and complications in Crohn’s disease
Special Collection
Introduction
While observational studies have shown a role for 
macronutrients as risk factors for inflammatory 
bowel disease (IBD), fewer studies have investi-
gated that of micronutrients.1–4 Nonetheless, it is 
well recognized that micronutrients have a relevant 
impact on different biological processes in IBD 
pathophysiology such as adaptive and innate 
immunity, and integrity of gastrointestinal 
barrier.1 Zinc is a micronutrient, which has been 
linked to inflammatory diseases such as IBD. 
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Background: Zinc deficiency (ZD) in Crohn’s disease (CD) is considered a frequent finding and 
may exacerbate CD activity. ZD is associated with depression in non-CD patients. We aimed 
to assess the prevalence of ZD in CD patients in clinical remission, its association with mood 
disturbances and to analyze a potential impact on future disease course.
Methods: Zinc levels from CD patients in clinical remission at baseline and an uncomplicated 
disease course within the next 3 years (n = 47) were compared with those from patients 
developing complications (n = 50). Baseline symptoms of depression and anxiety were 
measured with the Hospital Anxiety and Depression scale.
Results: Mean zinc level in the 97 patients (40.4 ± 15.7 years, 44.3% males) was 18.0 ± 4.7 
μmol/l. While no ZD (<11 μmol/l) was observed, we found low zinc levels (<15.1 μmol/l) in 28 
patients (28.9%). Males had higher zinc levels compared with females (19.4 ± 5.7 versus 16.8 
± 3.3, p = 0.006). Patients with low zinc levels more often reported depression symptoms 
compared with patients with higher levels (27.3 versus 9.4%, p = 0.047). In a multivariate 
analysis, zinc levels were an independent negative predictor for depression symptoms [odds 
ratio (OR) 0.727, 95% confidence interval (CI) 0.532–0.993, p = 0.045]. Zinc levels of patients 
with a complicated disease course were not different from those of patients without (17.7 ± 
4.3 versus 18.3 ± 5.1, n.s.). Baseline zinc levels did not predict disease outcome regardless of 
ATG16L1 genotype.
Conclusion: Low–normal zinc levels were an independent predictor for the presence of 
depression symptoms in CD patients. Zinc levels at baseline did not predict a complicated 
disease course, neither in CD patients overall, nor ATG16L1T300A carriers.
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Zinc deficiency (ZD) appears to compromise gas-
trointestinal barrier function, which can perpetu-
ate different diseases such as celiac disease, 
chronic diarrhea or IBD.5 There are several path-
ways demonstrating how zinc or ZD may interact 
with these diseases. First, zinc plays a crucial role 
in the development and function of cells mediat-
ing innate immunity,6 has direct anti-inflamma-
tory effects via zinc-finger protein A20,7 and has 
a positive effect on intestinal tight junctions8 and 
intestinal repair.9 Furthermore, zinc can act via 
metallothioneins (MTs). MTs are a family of 
small proteins with a high cysteine content at con-
served positions that are rapidly upregulated in 
response to an inflammatory stimulus such as 
tumor necrosis factor (TNF).10 MT function 
seems to be dependent upon the presence of 
zinc.11 Effects of MTs include reduction of 
apoptosis12 and antimicrobial activity.13 Finally, 
zinc is critical for early and late autophagy.14 
Autophagy is thought to suppress inflammation 
via degradation of inflammasomes and inflamma-
some-agonists.14 Genome-wide association stud-
ies revealed an association between a single 
nucleotide polymorphism in ATG16L1 – a key 
player in autophagy – and Crohn’s disease 
(CD).15 In view of the latter, ZD might increase 
the impact of ATG16L1 polymorphisms.
Zinc deficiency is common in CD, with up to one 
third of all patients presenting with low serum zinc 
levels,16 even in patients in clinical remission.17 ZD 
in turn may exacerbate CD by increasing mucosal 
permeability, leading to neutrophil transmigration 
and luminal antigen permeation.18 Such increased 
mucosal permeability has been shown to correlate 
with both, CD activity19 and relapse probability.20 
Despite high prevalence of ZD in IBD and its 
links to inflammation, so far no study investigated 
the role of serum zinc as a potential predictive 
serum marker for future disease course and its 
potential causative role in patients with a low or 
absent inflammatory disease activity.
Zinc levels have also been implicated in psychiat-
ric disorders, where zinc is involved in several neu-
robiological and inflammation processes affecting 
mood.21–23 Increasing evidence suggest an associa-
tion between low serum zinc levels and depres-
sion;23–28 however, whether this also applies to 
patients with IBD is, as yet, unknown. Scrutinizing 
the relationship of ZD with psychiatric symptom-
atology in IBD seems particularly important, as 
24% and 37% of patients with CD have 
depression and anxiety, respectively, with these 
prevalence rates being almost twice as high in 
patients with active IBD.29 Both, depression and 
anxiety predict clinical recurrence in patients with 
CD30 and a bi-directional link between depressive 
mood and anxiety with the inflammatory response 
and disease course in IBD has been proposed.31 
Particularly in the context of clinical disease remis-
sion, low serum zinc levels due to intestinal dis-
ease activity might be an important contributor to 
psychological symptoms in CD patients. Despite 
the high prevalence of both, ZD and symptoms of 
depression and anxiety in IBD patients, the impact 
of zinc levels and symptoms of depression or anxi-
ety in IBD patients has not been explored. Table 
1 provides a summary of existing and new knowl-
edge regarding zinc deficiency.
We therefore aimed to assess the prevalence of 
ZD in CD patients in clinical remission and to 
analyze both a potential impact on future disease 
course as well as an interaction with mutations in 
ATG16L1. We further aimed to examine the 
association of zinc levels with symptoms of anxi-
ety and depression.
Methods
Patients
The Swiss IBD cohort study (SIBDCS) is a nation-
wide cohort study from all regions of Switzerland, 
which has been including patients meeting the 
diagnostic criteria for IBD in accordance to estab-
lished guidelines.32 Enrollment started in 2006. 
The SIBDCS is supported by the Swiss National 
Science Foundation and is approved by the local 
ethics committees of the participating centers 
(institutional review board no. EK-1316, approved 
on 5 February 2007). Written informed consent 
was obtained from all patients before enrollment 
into the study. Inclusion criteria for the SIBDCS 
have been published elsewhere.33 All CD patients 
currently enrolled in the SIBDCS were screened 
for eligibility. For this study, only CD patients with 
a minimum follow-up period of 1 year were 
selected. In order to analyze the impact of zinc on 
future disease course, only patients with disease 
remission at baseline were selected based on a 
Crohn`s Disease Activity Index (CDAI) ⩽ 150 
and absent endoscopic or histological disease activ-
ity (if endoscopy and histological examinations 
were performed). Further inclusion criteria were: 
(a) age ⩾ 18 years, (b) documented evidence/
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presence of CD prior to cohort enrollment, and (c) 
either complicated or uncomplicated disease 
course during the follow-up period (1:1 ratio) 
according to the definition below. Exclusion crite-
ria were: (a) documented evidence/presence of 
ulcerative colitis (UC), (b) evident inflammatory 
disease activity (one of the following) [CDAI > 
150, active endoscopic disease activity (if applica-
ble), histologic findings of chronic or acute inflam-
mation on biopsies (if applicable), active clinical 
disease course], (c) any zinc supplementation 
products at baseline or during the follow-up 
period. Patients were selected for further analyses 
and serum zinc testing, aimed at obtaining roughly 
equal fractions of patients with versus without 
future complicated disease course (as defined 
below) within the follow-up period (roughly 1:1 
ratio). A sample size of 44 patients in each group 
would detect a difference in serum zinc levels of 
1.5 μmol/l between CD without complicated dis-
ease course and CD with a future complicated dis-
ease course with a power of 80% (alpha error 0.05, 
standard deviation 2.5 μmol/l). A standard devia-
tion of 2.5 μmol/l was chosen based on a recent 
publication by Beckett and colleagues.34 In another 
study regarding serum zinc levels in CD and UC, 
standard deviation ranged from 1.9 to 2.1 μmol/l.16
Definitions
Future complicated disease course was defined as 
any one of the following: (a) flare up or (b) need 
for new anti-TNF, or (c) development of steno-
sis, abscess, fistula or anal fissure, adapted from 
previously suggested criteria.35 Uncomplicated 
disease course was defined as the absence of all 
the abovementioned criteria for complication and 
a CDAI of <220. Zinc deficiency was defined as 
serum levels of less than 11 μmol/l (normal range 
11–24 μmol/l).36 Low–normal zinc values were 
defined as below the 30th percentile of the nor-
mal range. For simplification, this cut-off (14.9) 
was rounded up in order to consider the range 
11–15 μmol/l as low–normal.
Data collection
All clinical data were available from the SIBDCS. 
Zinc was measured from serum tubes stored at 
−70°C. Analysis was performed by a commercial 
laboratory (Unilabs, Coppet VD, Switzerland) 
using ion-coupled-plasma-mass spectroscopy 
(ICP-MS Varian 820). To rule out the possibility 
of factitious zinc contamination of serum samples 
due to long-term frozen sample storage in con-
ventional serum tubes, a pilot study was con-
ducted with 10 random serum samples from the 
SIBDCS data center (see results section). The 
following clinical variables were collected from 
the SIBDCS: patient demographics (age at enroll-
ment, sex, BMI, smoking status), baseline disease 
characteristics and activity (stool frequency, 
CDAI, disease localization, date of first symp-
toms, date of diagnosis, diagnostic delay, past and 
Table 1. Summary of existing and new knowledge regarding zinc deficiency.
What is known
ZD is considered a common finding in CD with up to one third of all patients presenting with low serum zinc 
levels. ZD is found even in patients in clinical remission
ZD may exacerbate CD activity, however long-term observational data are missing
ZD interferes with early and late autophagy, while an ATG16L1 mutation, which is involved in autophagic 
processes, has been linked to CD
ZD is associated with depression in non-CD patients. However, data on IBD patients are lacking, although 
up to 25% of CD patients have depression symptoms
What is new
In a cohort of 97 CD patients with disease remission, no single case of ZD has been identified
Nonetheless, low-normal zinc levels were an independent predictor for the presence of depression 
symptoms in CD patients
Zinc levels at baseline did not predict complicated disease course, neither in CD patients overall nor 
ATG16L1T300A carriers
ZD, zinc deficiency; CD, Crohn’s disease; IBD, inflammatory bowel disease.
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current treatments), follow-up disease character-
istics and activity (CDAI, past and current medi-
cations, complications, stool frequency, flares) 
and genetic data regarding single nucleotide poly-
morphism (SNP) rs2241880 (ATG16L1 gene 
variant).15 The ATG16L1 polymorphism occurs 
in three isoforms: homozygous wild-type (AA), 
heterozygous (AG) and homozygous variant 
(GG).37 Depression and anxiety symptoms were 
measured in the SIBDCS at baseline and during 
the follow-up period according to Zigmond and 
Snaith; The Hospital Anxiety and Depression 
Scale (HADS) is a self-assessment mood scale 
developed for outpatients comprising 14 ques-
tions graded on a 4-point Likert scale with sub-
scales of anxiety and depression (total score 0–21, 
while 0–7 were considered normal, 8–10 indica-
tive of mild, 11–14 indicative of moderate, and 
15–21 indicative of severe anxiety/depression).38
Statistical analysis
For statistical analysis, the IBM Software SPSS 
Statistics Version 22.0.0 (2013, SPSS Science, 
Inc., Chicago, IL) was used. Complete data were 
analyzed in a pooled manner, with further separate 
consecutive analysis for patients with a future com-
plicated versus a future uncomplicated disease 
course. Categorical data are depicted as percent-
age of the group total. For comparisons between 
continuous variables, two-sample t test and Mann–
Whitney U test were used depending on whether 
data were normally distributed or not. Comparison 
between categorical data was performed with the 
Chi-square test. For correlation studies investigat-
ing the influence of zinc levels on stool frequency 
and anxiety/depression symptoms, the Pearson 
and Spearman tests were used, respectively. 
Multivariate logistic regression regarding predic-
tion of low zinc levels for future CD outcome and 
for presence of depression symptoms was per-
formed by first taking into account all covariates 
with a univariate p value of <0.15, removing insig-
nificant covariates, and then adding remaining 
covariates one by one, checking the model signifi-
cance and consistency at each step. For the pur-
poses of this study, a p value of <0.05 was 
considered statistically significant.
Results
Patient demographics
A total of 97 patients, 50 with a complicated and 
47 with an uncomplicated future disease course, 
were analyzed. Mean age was 40.4 years (±15.7); 
43 were males (44.3%). Median duration of CD 
at baseline was 6.6 years [interquartile range 
(IQR) 2.6–15.6 years]. All patients were in clini-
cal remission at study enrollment with a median 
CDAI at baseline of 34.0 (IQR 11.0–53.0). A 
sum of 26 patients (26.8%) were current smok-
ers. Mean BMI was 23.9 kg/m2 (±4.2 kg/m2). 
According to the Montreal classification, 36 
patients had ileal disease (L1, 37.1%), while 23 
had colonic (L2, 23.7%) and 31 had ileocolonic 
(L3, 32.0%) disease at baseline. In four patients 
(4.1%), isolated upper gastrointestinal tract dis-
ease (L4) was reported. Four patients with ileal 
and colonic disease had additional upper gastro-
intestinal tract involvement (one patient with L1 
and three patients with L2). In three patients, 
Montreal classification was not applicable. 
Median diagnostic delay (time from first symp-
toms to diagnosis) was 7.5 months (IQR 1.0–27.5 
months). No prior or current anti-tumor necrosis 
factor (TNF) treatment was reported. None of 
the patients received any zinc supplementation 
products. Median frequency of liquid stools (per 
week) at baseline was 0 (IQR 0–14). Although all 
patients were in clinical remission at baseline, 
patients with a future complicated disease course 
had higher CDAI scores (but still ⩽150) and 
reported longer CD duration than patients who 
did not experience complications in the follow-up 
period. Otherwise, no differences were seen 
between the two groups at baseline evaluation, 
including in psychiatric symptoms. For a detailed 
synopsis over the whole study population and a 
comparison between group 1 (complicated future 
disease course) and group 2 (uncomplicated 
future disease course), see Table 2.
Zinc pilot analysis
Given the fact that special trace element free 
tubes are frequently used for zinc analysis, 
because of possible interference of minimal 
amounts of trace elements in the serum tube 
itself, we first conducted a pilot study to evaluate 
accuracy of zinc analysis from 10 random serum 
samples stored at the SIBDCS datacenter. Results 
from those samples are depicted in Supplementary 
Figure 1. Mean zinc level was 11.8 μmol/l with a 
median of 11.8 μmol/l and a total range of 6.5–16 
μmol/l. In eight samples, zinc level was within the 
normal range, which is 11–24 μmol/l, while the 
remaining two samples (20%) showed reduced 
zinc levels. None of the samples showed an 
T Greuter, Y Franc et al.
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Table 2. Baseline patient and disease characteristics.
All patients  
(n = 97)
Complicated future 
disease course (n = 50)
Uncomplicated future 
disease course (n = 47)
Age in years, mean (SD) 40.4 (15.7) 43.2 (15.1) 37.5 (15.9)
Sex  
  − Male 43 (44.3%) 22 (44.0%) 21 (44.7%)
  − Female 54 (55.7%) 28 (56.0%) 26 (55.3%)
BMI in kg/m2, mean (SD) 23.9 (4.2) 24.2 (4.7) 23.5 (3.5)
Duration of CD at 
enrolment in years, 
median (IQR)
6.6 (2.6–15.6) 9.0 (3.7–21.0) 4.2 (1.1–14.3)a
Diagnostic delay in 
months, median (IQR)
7.5 (1.0–27.5) 8.0 (1.0–24.5) 7.0 (2.0–36.0)
Current smoking status  
  − Yes 26 (26.8%) 12 (24.0%) 14 (29.8%)
  − No 55 (56.7%) 26 (52.0%) 29 (61.7%)
  − Missing 16 (16.5%) 12 (24.0%) 6 (8.5%)
Past IM  
  − Yes 16 (16.5%) 10 (20.0%) 6 (12.8%)
  − No 81 (83.5%) 40 (80.0%) 41 (87.2%)
Anti-TNF naïve  
  − Yes 97 (100%) 50 (100%) 47(100%)
  − No 0 0 0
Current treatment  
  − 5-ASA 20 (20.6%) 9 (18.0%) 11 (23.4%)
  − AZA/6-MP 43 (44.3%) 26 (52.0%) 17 (36.2%)
  − Topical steroids 27 (27.8%) 14 (28.0%) 13 (27.7%)
  − MTX 5 (5.2%) 2 (4.0%) 3 (6.4%)
  − None 19 (19.6%) 7 (14.0%) 12 (25.5%)
Disease localization  
  − L1 36 (37.1%) 17 (34.0%) 19 (40.4%)
  − L2 23 (23.7%) 12 (24.0%) 11 (23.4%)
  − L3 31 (32.0%) 18 (36.0%) 13 (27.7%)
  − L4 4 (4.1%) 2 (4.0%) 2 (4.3%)
  − Missing 3 (3.1%) 1 (2.0%) 2 (4.3%)
CDAI, median (IQR) 34.0 (11.0–53.0) 38.0 (22.3–53.8)a 21.0 (6.0–42.5)b
Number of liquid stools 
per week, median (IQR)
0.0 (0.0–14.0) 1.0 (0.0–14.0) 0.0 (0.0–7.0)
(Continued)
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elevated zinc level. Accordingly, measuring zinc 
from normal serum tubes did not induce false-
high results and indeed, reflected adequate levels 
within an anticipated range.
Zinc levels
Mean zinc level in the study population was 18.0 
± 4.7 μmol/l. No absolute ZD (defined as <11 
μmol/l) was observed. Low zinc levels (defined 
as <15.1 μmol/l) were found in 28 patients 
(28.9%). Males had significantly higher zinc lev-
els compared with females (19.4 ± 5.7 μmol/l 
versus 16.8 ± 3.3 μmol/l, p = 0.006), and the 
proportion of patients with low zinc levels was 
higher among females (20/54, 37.0% versus 8/43, 
18.6%, p = 0.047). Patients with a longer diag-
nostic delay (>23.9 months) showed a trend 
towards higher proportion of low zinc levels 
(11/26, 42.3% versus 12/42, 22.2%, p = 0.063). 
Figure 1. Proportion of patients with low serum zinc level according to sex, stool frequency, diagnostic delay, 
presence of depression symptoms and presence of ATG16L1 risk variants.
All patients  
(n = 97)
Complicated future 
disease course (n = 50)
Uncomplicated future 
disease course (n = 47)
HADS anxiety score, 
median (IQR)
6 (3–9) 6 (4–9) 5.5 (2.25–8)
HADS depression score, 
median (IQR)
3 (1–6) 4 (2–6) 2.5 (0–5)
Follow up  
  − 1y 12 (12.4%) 2 (4.0%) 10 (21.3%)
  − 2y 15 (15.5%) 6 (12.0%) 9 (19.1%)
  − 3y or + 70 (72.2%) 42 (84.0%) 28 (59.6%)c
aDuration of CD at enrollment was significantly longer in group 1 (future complicated disease course) compared with 
group 2 (uncomplicated disease course), p = 0.018.
bCDAI at baseline was significantly higher in group 1 compared with group 2, p = 0.014.
cA 3 years or more follow up was reported more often in group 1 compared with group 2, p = 0.009.
SD, standard deviation; CD, Crohn’s disease; BMI, body mass index; TNF, tumor necrosis factor; IQR, interquartile range; 
IM, Immunomodulation; HADS, Hospital Anxiety and Depression Scale; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine; 
6-MP, 6-mercaptopurine; MTX, methotrexate; L1, Montreal classification ileal disease; L2, Montreal classification colonic 
disease; L3, Montreal classification ileocolonic disease; L4, Montreal classification isolated upper gastrointestinal tract 
disease; CDAI, Crohn’s disease activity index.
Table 2. (Continued)
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Patients with more than seven liquid stools per 
week (n = 29) more frequently had low serum 
zinc levels (13/29, 44.8%) compared with 
patients with seven or less liquid stools (15/62, 
24.2%, p = 0.047). For details, see Figure 1. 
However, serum zinc levels did not significantly 
correlate with number of liquid stools at base-
line (rho –0.113, p = 0.285). In a univariate 
regression model, female sex, stool frequency, 
diagnostic delay and immunosuppression at 
baseline were relevant predictors for low serum 
zinc levels (p < 0.15). When those factors were 
analyzed in a multivariate regression model, 
immunosuppression remained the only signifi-
cant predictor, while stool frequency showed at 
least a trend towards statistical significance. For 
univariate and multivariate analyses, see Table 3.
Anxiety and depression symptoms
A total of 27 of the 97 patients (27.8%) reported 
at least mild anxiety symptoms at baseline evalu-
ation (including 9 patients with moderate and 1 
with severe anxiety). Median HADS anxiety score 
was 6 (IQR 3–9). Depression symptoms were 
reported by 11 of the 97 patients (11.3%): seven 
patients had mild, four had moderate, and none 
had severe depression at baseline. Median HADS 
depression score was 3 (IQR 1–6). Zinc levels and 
anxiety score did not show any correlation, nor 
did zinc levels and classification into normal, 
mild, moderate and severe anxiety. However, we 
found a mild, but significant correlation between 
zinc levels and severity of depression (rho –0.277, 
p = 0.016). Patients with low serum zinc levels 
significantly more often reported depression 
symptoms compared with patients with higher 
serum zinc levels (6/22, 27.3% versus 5/53, 9.4%, 
p = 0.047). In a multivariate regression model 
corrected for stool frequency and CDAI, zinc lev-
els at baseline were an independent negative pre-
dictor for the presence of depression symptoms 
[odds ratio (OR) 0.727, 95% confidence interval 
(CI) 0.532–0.993, p = 0.045]. For details see 
Table 4.
Single nucleotide polymorphism analysis
ATG16L1 SNP analysis was available from 61 
patients (62.9%) with 25 (25/61, 41.0%) being 
homozygous for the risk variant rs2241880 
(T300A), while 23 patients were heterozygotes. 
Zinc levels of patients with ATG16L1T300A 
(homozygotes) did not differ from those of patients 
without or with only one risk allele (16.3 ± 2.7 
μmol/l versus 17.1 ± 3.2 μmol/l, n.s.). In addition, 
the proportion of low serum zinc levels did not 
show any significant differences between the two 
groups: low zinc levels were found in 10 out of the 
25 patients carrying the risk variant and in 11 out 
of the 36 patients without the risk variant (40.0% 
versus 30.6%, n.s). In a regression model, pres-
ence of ATG16L1T300A did not predict low serum 
zinc levels. For details, see Table 3.
Prediction of future complicated disease course
Patients were followed for 1 (12, 12.4%), 2 (15, 
15.5%) or 3 years and longer (70, 72.2%). The 
following complications occurred: 29 patients 
(29/50, 58.0%) experienced a flare up, 26 
patients (26/50, 52.0%) needed new anti-TNF 
treatment, and 45 patients (45/50, 90.0%) devel-
oped stenosis, abscess, fistula or anal fissure. 
Zinc levels of patients with a future complicated 
disease course were not different from those of 
patients without complications (17.7 ± 4.3 
μmol/l versus 18.3 ± 5.1 μmol/l, n.s.). Proportions 
of patients with low serum zinc levels were com-
parable with 16 out of 50 (32.0%) in the compli-
cated disease group and 12 out of 47 (25.5%) in 
the uncomplicated disease group (n.s.). We did 
not observe any differences when females/males 
were analyzed separately. Looking only at 
ATG16L1T300A carriers, no difference in zinc lev-
els between patients with versus without a com-
plicated disease course was seen (16.0 ± 2.6 
μmol/l versus 17.3 ± 2.9 μmol/l, n.s). After 
screening the potential predictors for future dis-
ease outcome one by one, the variables age, 
CDAI at baseline, stool frequency and presence 
of ATG16L1T300A were retained in the multiple 
predictor model in addition to serum zinc levels 
(see Table 5). Presence of ATG16L1T300A 
seemed to be the only predictive variable, 
although statistical significance was not achieved 
(p = 0.053). Nevertheless, neither absolute zinc 
levels at baseline nor presence of low serum zinc 
levels (<15.1 μmol/l) predicted future compli-
cated disease course.
Discussion
This analysis of prospectively obtained data from 
a nationwide cohort study in Switzerland tested 
for an association of serum zinc levels and psychi-
atric symptoms, stool frequency and future dis-
ease course in CD patients in clinical remission at 
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baseline. In our subset of SIBDCS patients with 
CD in clinical remission, we did not observe ZD. 
However, zinc levels revealed to be low–normal in 
a considerable proportion of patients. Zinc levels 
were lower among females when compared with 
their male counterparts as well as among those 
patients with more than seven liquid stools per 
week. Intriguingly, lower zinc levels were an inde-
pendent predictor for depression, but not anxiety 
symptoms. Zinc levels at baseline did not predict 
complicated disease course, neither in CD patients 
overall nor ATG16L1T300A carriers. Yet, in the lat-
ter, we observed a clear albeit nonsignificant trend 
towards an increase in complications in both uni-
variate and multivariate testing.
In contrast to the studies conducted by Vagianos 
and colleagues16 and Filippi and colleagues,17 
who reported zinc deficiency in up to 65% even in 
patients with clinical remission, we did not iden-
tify a single case with serum zinc levels below the 
reference value of 11μmol/l. When we compare 
our demographic data with that of Filippi and 
colleagues, our patients had lower CDAI (mean 
37.5 versus 89.7) and did not report any previous 
CD-related surgery, while nearly 50% of the 
patients studied by Filippi and colleagues had 
undergone ileal, ileocecal or colonic resection.17 
Therefore, presence of ZD may have been overes-
timated by previous studies not exclusively con-
sidering CD patients in remission. Data on the 
impact of sex on serum zinc levels are conflicting; 
in contrast to other micronutrient studies, but in 
accordance to findings from the National Health 
and Nutrition Examination Survey study, we found 
significant sex-specific differences, with lower 
zinc levels among females.39–42 This is particularly 
noteworthy, as it has been previously described 
that daily intake of zinc (assessed with the use of 
prospective food records for three days) was 
higher among females compared with males, 
which may not be the case in our cohort.17 
However, influence of sex on zinc levels may be 
biased by several confounders such as stool fre-
quency, diagnostic delay and immunosuppressive 
therapy, as in a multivariate regression model cor-
rected for those variables, sex was not an inde-
pendent predictor for low serum zinc levels. 
Accordingly, our results should be replicated in a 
larger IBD study population.
The proportion of patients with low serum zinc 
levels tended to be higher among patients with 
more than seven liquid stools per week. Thus, low 
serum zinc may be a promotor of diarrhea or 
higher stool frequency in the presence of clinical 
and endoscopic disease remission. This finding is 
supported by prior studies demonstrating 
increased gut permeability in the context of zinc 
deficiency and by studies testing zinc supplemen-
tation for treatment of acute diarrhea.18,43–45 
Therapeutic effects of zinc might be attributable 
to reduction of a transmucosal leak and to a 
K-channel blockage of adenosine 3-5-cyclic 
monophosphate-mediated chlorine secretion.43,46 
Therefore, even in the absence of absolute zinc 
deficiency, low zinc levels might be clinically rel-
evant, promoting diarrhea and elevated stool fre-
quency. However, the opposite might also be the 
case: increased frequency of liquid stools leads to 
a decrease in serum zinc levels. More clinical data 
is needed to assess direction of this association 
and in order to generate clear recommendations 
regarding zinc supplementation in CD patients 
with low–normal zinc levels.
In our study, the ATG16L1 risk variant was an 
independent risk factor for future CD outcome, 
bordering significance in the multivariate analy-
sis, which contrasts the finding from Cleynen and 
colleagues which could not show any association 
of risk gene variants and disease outcome.47 
However, low serum zinc levels did not have a 
different effect on stool frequency or disease out-
come when comparing those patients harboring 
the risk variant versus those that did not. Thus, 
the hypothesis that zinc deficiency or low zinc lev-
els might increase the impact of ATG16L1 could 
not be supported. One explanation might be that 
a mutated ATG16L1 disrupts autophagy to an 
extent, that any potential additional effect of low 
zinc becomes negligible.
Several epidemiological and animal studies have 
shown an association between low serum zinc lev-
els and depression symptoms.23–28,48,49 In addition, 
at least some evidence for zinc supplementation 
can be derived from randomized controlled-trials 
with patients in clinical depression.50,51 However, 
until now, to the best of our knowledge, no study 
has linked serum zinc levels and depression symp-
toms in patients with IBD. In a multivariate 
regression model correcting for relevant con-
founders such as CDAI or stool frequency, we 
were able to show that low serum zinc levels are an 
independent predictor for depression symptoms. 
This is noteworthy, given a previous study from 
the Swiss IBD cohort showing that depression is 
Therapeutic Advances in Gastroenterology 11
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associated with higher rates of clinical recurrence 
of IBD.30 Considering that we evaluated patients 
in clinical remission only and none of those had 
absolute zinc deficiency, the inverse effect of zinc 
on psychiatric symptoms might be even stronger 
in a larger population with more severe and active 
disease and further studies are warranted. In fact, 
the percentage of patients in the current study 
with clinically relevant (i.e. at least mild) symp-
toms of depression (11%) or anxiety (28%) was 
only half of the level expected from recent meta-
analytic data.29 This low level of psychological dis-
tress could also be an explanation for the lack of 
an association between anxiety and zinc level in 
our patients. To compare, lower serum zinc levels 
were significantly associated with more severe 
anxiety symptoms in female students from Iran, of 
whom 66% had at least mild anxiety measured 
with the HADS.52 Also, a series of carefully con-
ducted animal studies imply a role of zinc defi-
ciency in anxiety-like behaviors.53
It is advocated that patients with IBD should be 
screened for psychological comorbidities, includ-
ing depressive symptoms, and psychological sup-
port should be a part of standard care for those in 
need.54 However, whether zinc levels in CD 
patients with relevant depressive symptoms should 
be tested to start supplementation therapy in case 
of nutritional deficiency has yet to be determined. 
Currently available evidence as to whether zinc 
supplementation alleviates depressive symptoms 
in humans (without IBD) is scarce and conflict-
ing.22 Nonetheless, our findings provide a ration-
ale for zinc supplementation in CD patients with 
depressive symptoms, potentially even in patients 
with low–normal serum zinc levels.
Our study has several strengths and some limita-
tions. We provide the first study evaluating an 
association of serum zinc levels and psychiatric 
symptoms in CD patients. In addition, it is the 
first analysis that evaluates the effect of zinc levels 
on future disease course with regards to the pres-
ence or absence of the ATG16L1 risk variant, 
therefore linking epidemiological observations 
with molecular disease mechanisms. The SIBDCS 
is a large and well-established cohort with struc-
tured annual physician- and patient-based assess-
ments. However, albeit the prospective nature of 
data acquisition, retrospective analysis with 
annual follow-up visits only may be associated 
with underreporting of symptoms in general and 
psychiatric symptoms in particular. A limitation 
of our study is that significantly more patients in 
the future complicated disease group had a follow 
up of 3+ years compared with those not experi-
encing any complications, which might lead to 
underreporting of late complications in the 
uncomplicated disease course group. However, as 
we only took into account the first complication 
(being sufficient to fall into the complication cat-
egory), we feel rather confident to assume the two 
groups and their follow up to be comparable. Our 
study might be underpowered to detect weaker 
effects of ZD on disease course. The role of zinc 
may have been underestimated, since all patients 
were in clinical remission at baseline without 
frank zinc deficiency. Although all patients were 
in clinical remission at baseline, patients with a 
future complicated disease course had higher 
CDAI values at first visit and reported a longer 
CD duration. This slightly, but significantly 
higher clinical disease activity and the longer dis-
ease duration might be considerable confounders 
of our analysis. And finally, zinc levels were only 
measured at baseline, but not during follow up 
and during flares, although, presumably, these 
levels are prone to fluctuations, which should be 
taken into account in future studies.
Taken together, zinc deficiency in CD patients 
with clinical remission did not seem to be as rel-
evant as previously thought based on the rather 
sparse literature. However, low serum zinc levels 
were an independent predictor for presence of 
depression symptoms. Whether supplementa-
tion can be recommended in those patients in 
general has to be determined in the future. In the 
absence of active disease, low zinc levels did not 
predict complicated disease course regardless of 
ATG16L1 genotype.
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